The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Recent updates on drug resistance in Mycobacterium tuberculosis
Abstract
Tuberculosis (TB) along with acquired immune deficiency syndrome and malaria rank among the top three fatal infectious diseases which pose threat to global public health, especially in middle and low income countries. TB caused by Mycobacterium tuberculosis (Mtb) is an airborne infectious disease and one-third of the world's population gets infected with TB leading to nearly 1·6 million deaths annually. TB drugs are administered in different combinations of four first-line drugs (rifampicin, isoniazid, pyrazinamide and ethambutol) which form the core of treatment regimens in the initial treatment phase of 6-9 months. Several reasons account for the failure of TB therapy such as (i) late diagnosis, (ii) lack of timely and proper administration of effective drugs, (iii) lower availability of less toxic, inexpensive and effective drugs, (iv) long treatment duration, (v) nonadherence to drug regimen and (vi) evolution of drug-resistant TB strains. Drug-resistant TB poses a significant challenge to TB therapy and control programs. In the background of worldwide emergence of 558 000 new TB cases with resistance to rifampicin in the year 2017 and of them, 82% becoming multidrug-resistant TB (MDR-TB), it is essential to continuously update the knowledge on the mechanisms and molecular basis for evolution of Mtb drug resistance. This narrative and traditional review summarizes the progress on the anti-tubercular agents, their mode of action and drug resistance mechanisms in Mtb. The aim of this review is to provide recent updates on drug resistance mechanisms, newly developed/repurposed anti-TB agents in pipeline and international recommendations to manage MDR-TB. It is based on recent literature and WHO guidelines and aims to facilitate better understanding of drug resistance for effective TB therapy and clinical management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
Molecular mechanisms of antibiotic resistance
Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. V. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3380 · Cited by 4,092
Mechanisms of Antibiotic Resistance
Munita, J. M., & Arias, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0016-2015 · Cited by 2,782
Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer
von Wintersdorff, C. J. H., Penders, J., van Niekerk, J. M., Mills, N. D., Majumder, S., van Alphen, L. B., Savelkoul, P. H. M., & Wolffs, P. F. G. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00173 · Cited by 1,707
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Aminoglycoside modifying enzymes
Ramirez, M. S., & Tolmasky, M. E. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.08.003 · Cited by 1,464
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria
Piddock, L. J. V. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.382-402.2006 · Cited by 1,231 · cited 1×
“2) (Piddock 2006; Blair et al. 2015; Nguyen 2016; Nasiruddin et al. 2017).”
Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis
Seung, K. J., Keshavjee, S., & Rich, M. L. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017863 · Cited by 805
Multidrug Tolerance of Biofilms and Persister Cells
Lewis, K. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-75418-3_6 · Cited by 804
Mycobacterium tuberculosis: success through dormancy
Gengenbacher, M., & Kaufmann, S. H. E. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2012.00331.x · Cited by 696
Molecular Mechanisms Underlying Bacterial Persisters
Maisonneuve, E., & Gerdes, K. (2014) · Cell · doi:10.1016/j.cell.2014.02.050 · Cited by 645
Controlled drug release from pharmaceutical nanocarriers
Lee, J. H., & Yeo, Y. (2015) · Chemical Engineering Science · doi:10.1016/j.ces.2014.08.046 · Cited by 628
Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli
Velayati, A. A., Masjedi, M. R., Farnia, P., Tabarsi, P., Ghanavi, J., ZiaZarifi, A. H., & Hoffner, S. E. (2009) · Chest · doi:10.1378/chest.08-2427 · Cited by 607
Vaccine delivery using nanoparticles
Gregory, A. E., Titball, R., & Williamson, D. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00013 · Cited by 561
M. tuberculosis persistence, latency, and drug tolerance
Gomez, J. E., & McKinney, J. D. (2004) · Tuberculosis · doi:10.1016/j.tube.2003.08.003 · Cited by 533
Almeida Da Silva, P. E., & Palomino, J. C. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr173 · Cited by 532
Tuberculosis and lung damage: from epidemiology to pathophysiology
Ravimohan, S., Kornfeld, H., Weissman, D., & Bisson, G. P. (2018) · European Respiratory Review · doi:10.1183/16000617.0077-2017 · Cited by 531
Totally Drug-Resistant Tuberculosis in India
Udwadia, Z. F., Amale, R. A., Ajbani, K. K., & Rodrigues, C. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir889 · Cited by 527
Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives
Gygli, S. M., Borrell, S., Trauner, A., & Gagneux, S. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux011 · Cited by 457
Drug Resistance Mechanisms in Mycobacterium tuberculosis
Palomino, J., & Martin, A. (2014) · Antibiotics · doi:10.3390/antibiotics3030317 · Cited by 442
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
Falzon, D., Schünemann, H. J., Harausz, E., González-Angulo, L., Lienhardt, C., Jaramillo, E., & Weyer, K. (2017) · European Respiratory Journal · doi:10.1183/13993003.02308-2016 · Cited by 420
Mechanisms of Drug Resistance in Mycobacterium tuberculosis
Heym, B., Philipp, W., & Cole, S. T. (1996) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-80166-2_3 · Cited by 379
Quinolones: Action and Resistance Updated
Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., & Zhao, X. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789630947 · Cited by 376
Somoskovi, A., Parsons, L. M., & Salfinger, M. (2001) · Respiratory Research · doi:10.1186/rr54 · Cited by 373
Tuberculosis and chronic respiratory disease: a systematic review
Byrne, A. L., Marais, B. J., Mitnick, C. D., Lecca, L., & Marks, G. B. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.12.016 · Cited by 372
Dookie, N., Rambaran, S., Padayatchi, N., Mahomed, S., & Naidoo, K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx506 · Cited by 346
New agents for the treatment of drug-resistant Mycobacterium tuberculosis
Hoagland, D. T., Liu, J., Lee, R. B., & Lee, R. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.026 · Cited by 328
Seifert, M., Catanzaro, D., Catanzaro, A., & Rodwell, T. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119628 · Cited by 326
Marais, B. J., Lönnroth, K., Lawn, S. D., Migliori, G. B., Mwaba, P., Glaziou, P., Bates, M., Colagiuri, R., Zijenah, L., Swaminathan, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70015-x · Cited by 314
Lin, C.-H., Chen, C.-H., Lin, Z.-C., & Fang, J.-Y. (2017) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2017.02.001 · Cited by 298
Targeting Persisters for Tuberculosis Control
Zhang, Y., Yew, W. W., & Barer, M. R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06288-11 · Cited by 271
Tuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination
Raviglione, M. C., & Sulis, G. (2016) · Infectious Disease Reports · doi:10.4081/idr.2016.6570 · Cited by 266
Mechanisms of Drug Resistance in Mycobacterium tuberculosis
Zhang, Y., Vilchèze, C., & Jacobs, W. R. (2004) · Tuberculosis and the Tubercle Bacillus · doi:10.1128/9781555817657.ch8 · Cited by 261
Luthra, S., Rominski, A., & Sander, P. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02179 · Cited by 260
Antibiotic resistance mechanisms in M. tuberculosis: an update
Nguyen, L. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1727-6 · Cited by 249
First tuberculosis cases in Italy resistant to all tested drugs
Migliori, G. B., De Iaco, G., Besozzi, G., Centis, R., & Cirillo, D. M. (2007) · Weekly releases (1997–2007) · doi:10.2807/esw.12.20.03194-en · Cited by 219
Sun, G., Luo, T., Yang, C., Dong, X., Li, J., Zhu, Y., Zheng, H., Tian, W., Wang, S., Barry, C. E., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis601 · Cited by 192
Molecular Biology of Drug Resistance in Mycobacterium tuberculosis
Smith, T., Wolff, K. A., & Nguyen, L. (2012) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2012_279 · Cited by 190
The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis
Müller, B., Borrell, S., Rose, G., & Gagneux, S. (2013) · Trends in Genetics · doi:10.1016/j.tig.2012.11.005 · Cited by 183
Eldholm, V., Norheim, G., von der Lippe, B., Kinander, W., Dahle, U. R., Caugant, D. A., Mannsåker, T., Mengshoel, A. T., Dyrhol-Riise, A. M., & Balloux, F. (2014) · Genome Biology · doi:10.1186/s13059-014-0490-3 · Cited by 181
New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria
Nasiri, M. J., Haeili, M., Ghazi, M., Goudarzi, H., Pormohammad, A., Imani Fooladi, A. A., & Feizabadi, M. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00681 · Cited by 181
New drugs and perspectives for new anti-tuberculosis regimens ☆
Tiberi, S., Muñoz-Torrico, M., Duarte, R., Dalcolmo, M., D’Ambrosio, L., & Migliori, G.-B. (2018) · Pulmonology · doi:10.1016/j.rppnen.2017.10.009 · Cited by 179
Nanotechnology-Based Approach in Tuberculosis Treatment
Nasiruddin, M., Neyaz, M. K., & Das, S. (2017) · Tuberculosis Research and Treatment · doi:10.1155/2017/4920209 · Cited by 177
Trastoy, R., Manso, T., Fernández-García, L., Blasco, L., Ambroa, A., Pérez del Molino, M. L., Bou, G., García-Contreras, R., Wood, T. K., & Tomás, M. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-18 · Cited by 177
Hameed, H. M. A., Islam, M. M., Chhotaray, C., Wang, C., Liu, Y., Tan, Y., Li, X., Tan, S., Delorme, V., Yew, W. W., et al. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00114 · Cited by 175
Novel approaches to tuberculosis vaccine development
Kaufmann, S. H. E., Weiner, J., & von Reyn, C. F. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.10.018 · Cited by 160
Labby, K. J., & Garneau‐Tsodikova, S. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.80 · Cited by 140
Mechanisms of Drug Resistance in Mycobacterium tuberculosis
Cole, S. T. (1994) · Immunobiology · doi:10.1016/s0171-2985(11)80466-3 · Cited by 138
Lienhardt, C., Vernon, A., & Raviglione, M. C. (2010) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328337580c · Cited by 137
Targeting Phenotypically Tolerant Mycobacterium tuberculosis
Gold, B. S., & Nathan, C. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0031-2016 · Cited by 136
Ferlazzo, G., Mohr-Holland, E., Laxmeshwar, C., Hewison, C., Hughes, J. A., Jonckheere, S., Khachatryan, N., Avezedo, V. D., Egazaryan, L., Shroufi, A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30100-2 · Cited by 136
Targets for Combating the Evolution of Acquired Antibiotic Resistance
Culyba, M. J., Mo, C. Y., & Kohli, R. M. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00109 · Cited by 135
Tuberculosis elimination: where are we now?
Matteelli, A., Rendón, A., Tiberi, S., Al-Abri, S., Voniatis, C., Carvalho, A. C. C., Centis, R., D’Ambrosio, L., Visca, D., Spanevello, A., et al. (2018) · European Respiratory Review · doi:10.1183/16000617.0035-2018 · Cited by 132
Koch, A. S., Mizrahi, V., & Warner, D. F. (2014) · Emerging Microbes & Infections · doi:10.1038/emi.2014.17 · Cited by 129
Lee, A. S. G., Lim, I. H. K., Tang, L. L. H., Telenti, A., & Wong, S. Y. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.8.2087 · Cited by 127
Efflux Pump Gene Expression in Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates
Li, G., Zhang, J., Guo, Q., Jiang, Y., Wei, J., Zhao, L., Zhao, X., Lu, J., & Wan, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119013 · Cited by 127
Kurz, S. G., Furin, J. J., & Bark, C. M. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.02.010 · Cited by 113
MmpL Proteins in Physiology and Pathogenesis of M. tuberculosis
Melly, G. C., & Purdy, G. E. (2019) · Microorganisms · doi:10.3390/microorganisms7030070 · Cited by 113
Caws, M., Phan, M., Tho, D. Q., Lan, N. T. N., Hoa, D. V., & Farrar, J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00330-06 · Cited by 107
Carrier-Based Drug Delivery System for Treatment of Acne
Vyas, A., Sonker, A. K., & Gidwani, B. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/276260 · Cited by 97
Tuberculosis Infection and Latent Tuberculosis
Lee, S. H. (2016) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2016.79.4.201 · Cited by 93
Defining dormancy in mycobacterial disease
Lipworth, S., Hammond, R., Baron, V. O., Hu, Y., Coates, A. R. M., & Gillespie, S. H. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.05.006 · Cited by 90
Wang, K., Pei, H., Huang, B., et al. (2012) · Current Microbiology · doi:10.1007/s00284-012-0215-3 · Cited by 78
Farhat, M. R., Jacobson, K. R., Franke, M. F., Kaur, D., Sloutsky, A., Mitnick, C. D., & Murray, M. B. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02775-15 · Cited by 76
Liu, J., Shi, W., Zhang, S., Cassell, G., Maslov, D. A., Shur, K. V., Bekker, O. B., Даниленко, В. Н., Hao, X., & Zhang, Y. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00216 · Cited by 75
Modular epistasis and the compensatory evolution of gene deletion mutants
Echenique, J. I. R., Kryazhimskiy, S., Ba, A. N. N., & Desai, M. M. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1007958 · Cited by 69
Diversity and evolution of drug resistance mechanisms in Mycobacterium tuberculosis
Al-Saeedi, M., & Al‐Hajoj, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s144446 · Cited by 61
In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis
Xu, J., Wang, B., Fu, L., Zhu, H. J., Guo, S., Huang, H., Yin, D., Zhang, Y., & Lu, Y. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02155-18 · Cited by 60
Self-assembled Messenger RNA Nanoparticles (mRNA-NPs) for Efficient Gene Expression
Kim, H., Park, Y., & Lee, J. B. (2015) · Scientific Reports · doi:10.1038/srep12737 · Cited by 50
Chen, W., Green, K. D., Tsodikov, O. V., & Garneau‐Tsodikova, S. (2012) · Biochemistry · doi:10.1021/bi3004473 · Cited by 49
Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings
Sloan, D. J., & Lewis, J. M. (2016) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trv107 · Cited by 44
Tao, J., Han, J., HanYu, W., Hu, X., Deng, J., Fleming, J., Maxwell, A., Bi, L., & Mi, K. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1351 · Cited by 43
Kardan-Yamchi, J., Kazemian, H., Haeili, M., Harati, A. A., Amini, S., & Feizabadi, M. M. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.01.003 · Cited by 43
New regimens for reducing the duration of treatment of drug‐susceptible pulmonary tuberculosis
Conde, M. B., & Silva, J. R. L. E. (2011) · Drug Development Research · doi:10.1002/ddr.20456 · Cited by 38
TUBERCULOSIS IN TROPICAL AREAS AND IMMIGRANTS
Zammarchi, L., Bartalesi, F., & Bartoloni, A. (2014) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2014.043 · Cited by 35
Novel technologies: A weapon against tuberculosis
Hari, B. V., Chitra, K., Bhimavarapu, R., Karunakaran, P., Muthukrishnan, N., & Rani, B. S. (2010) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.71887 · Cited by 32
Honeyborne, I., Lipman, M. C. I., Zumla, A. I., & McHugh, T. D. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.02.006 · Cited by 26
New drugs and regimens for treatment of TB
Leibert, E. M., & Rom, W. N. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.60 · Cited by 20
Emerging drugs and drug targets against tuberculosis
Lambert, N., Abdalla, A. E., Duan, X., & Xie, J. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1258705 · Cited by 11
Khazaei, S., Rezaeian, S., Baigi, V., Saatchi, M., Molaeipoor, L., Khazaei, Z., Khazaei, S., & Raza, O. (2017) · Southern African Journal of Infectious Diseases · doi:10.1080/23120053.2017.1321243 · Cited by 8
Cited by
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
Metadata
- Authors
- Singh, R., Dwivedi, S. P., Gaharwar, U. S., Meena, R., Rajamani, P., & Prasad, T.
- Venue
- Journal of Applied Microbiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10-29
- Volume
- 128
- Issue
- 6
- Pages
- 1547-1567
- ISSN
- 1364-5072 (ISSN-L)
- 1365-2672
- OpenAlex
- W2979328457
- Cited by
- 337
- References
- 81
- FWCI
- 18.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.